SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Avax Technologies Inc – ‘8-K’ for 7/26/00

On:  Wednesday, 7/26/00, at 2:00pm ET   ·   For:  7/26/00   ·   Accession #:  912057-0-33224   ·   File #:  0-29222

Previous ‘8-K’:  ‘8-K’ on / for 7/26/00   ·   Next:  ‘8-K’ on 9/8/00 for 8/24/00   ·   Latest:  ‘8-K’ on / for 3/26/09

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 7/26/00  Avax Technologies Inc             8-K:5,7     7/26/00    7:43K                                    Merrill Corp/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         5     18K 
 2: EX-99.1     Miscellaneous Exhibit                                  2     12K 
 3: EX-99.2     Miscellaneous Exhibit                                  2     12K 
 4: EX-99.3     Miscellaneous Exhibit                                  2±    10K 
 5: EX-99.4     Miscellaneous Exhibit                                  2±    11K 
 6: EX-99.5     Miscellaneous Exhibit                                  2     14K 
 7: EX-99.6     Miscellaneous Exhibit                                  2     14K 


8-K   —   Current Report
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
2Item 5. Other Events
3Item 7. Financial Statements and Exhibits
8-K1st Page of 5TOCTopPreviousNextBottomJust 1st
 

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 --------------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 JULY 26, 2000 (APRIL 4, 2000) Date of Report (Date of earliest event reported) AVAX TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) DELAWARE 000-29222 13-3575874 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification Number) 4520 MAIN STREET SUITE 930 KANSAS CITY, MO 64111 (Address of principal executive offices) (816) 960-1333 (Registrant's telephone number, including area code)
8-K2nd Page of 5TOC1stPreviousNextBottomJust 2nd
ITEM 5. OTHER EVENTS The sole purpose of this Form 8-K to file the following press releases issued by the Company: 1) On April 4, 2000, the Company announced the presentation of data at the 91st Annual Meeting of the American Association for Cancer Research (AACR), which indicate that M-Vax-TM-, the Company's autologous cell vaccine (AC Vaccine-TM-) for the treatment of stage 3 melanoma, induces T cell infiltration of metastatic sites. 2) On April 5, 2000, the Company announced the presentation of preclinical data on its AC Vaccine technology, at the 91st Annual Meeting of the American Association for Cancer Research. The presentation outlined findings in a mouse model of breast cancer, indicating that vaccination with a vaccine developed using the Company's AC Vaccine technology resulted in improved relapse-free survival in mice. The study was supported by a grant from the Company and was conducted at the University of Illinois, Chicago. 3) On April 6, 2000, the Company announced that its Australian joint venture, AVAX Australia Pty. Limited (AVAX Australia) received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited, which was recently renamed Australian Vaccine Technologies, Ltd. (AVT). AVAX Australia holds the rights to manufacture and market M-Vax in Australia and has similar rights in New Zealand. Under the joint venture agreement, AVAX Australia has now received a total of $7.0 million (AUD) for AVT for a 35% interest in the joint venture entity. AVT also has the option to purchase an additional 15% interest for $3.0 million (AUD). 4) On May 15, 2000, the Company announced that it had initiated a Phase 1/2 study of L-Vax-TM-, the Company's autologous therapeutic cancer vaccine for leukemia, in patients with acute myelogenous leukemia (AML), a rapidly progressing cancer of the blood affecting immature cells of the bone marrow. 5) On May 22, 2000, the Company announced the presentation of data on O-Vax-TM-, the Company's AC Vaccine for the treatment of ovarian cancer, at the 36th Annual Meeting of the American Society of Clinical Oncology. 6) On May 23, 2000, the Company announced the presentation of data of M-Vax at the 36th Annual Meeting of the American Society of Clinical Oncology. The data confirm and expand the results of a study published in 1997 showing that M-Vax increases the survival rate of patients with advanced stage 3 melanoma, even after disease recurrence. 2
8-K3rd Page of 5TOC1stPreviousNextBottomJust 3rd
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. EXHIBITS. 99.1 Press Release dated April 4, 2000. 99.2 Press Release dated April 5, 2000. 99.3 Press Release dated April 6, 2000. 99.4 Press Release dated May 15, 2000. 99.5 Press Release dated May 22, 2000. 99.6 Press Release dated May 23, 2000. 3
8-K4th Page of 5TOC1stPreviousNextBottomJust 4th
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVAX TECHNOLOGIES, INC. Date: July 26, 2000 By: /s/ David L. Tousley --------------------------------- Name: David L. Tousley Title: Chief Financial Officer 4
8-KLast Page of 5TOC1stPreviousNextBottomJust 5th
EXHIBIT INDEX [Download Table] Exhibit Number Description -------------- ----------- 99.1 Press Release dated April 4, 2000. 99.2 Press Release dated April 5, 2000. 99.3 Press Release dated April 6, 2000. 99.4 Press Release dated May 15, 2000. 99.5 Press Release dated May 22, 2000. 99.6 Press Release dated May 23, 2000. 5

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘8-K’ Filing    Date First  Last      Other Filings
Filed on / For Period End:7/26/00148-K
5/23/0025
5/22/0025
5/15/0025
4/6/0025
4/5/0025
4/4/0015
 List all Filings 
Top
Filing Submission 0000912057-00-033224   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:46:07.1am ET